KR20240167718A - 인슐린 융합 단백질 - Google Patents

인슐린 융합 단백질 Download PDF

Info

Publication number
KR20240167718A
KR20240167718A KR1020247029510A KR20247029510A KR20240167718A KR 20240167718 A KR20240167718 A KR 20240167718A KR 1020247029510 A KR1020247029510 A KR 1020247029510A KR 20247029510 A KR20247029510 A KR 20247029510A KR 20240167718 A KR20240167718 A KR 20240167718A
Authority
KR
South Korea
Prior art keywords
fusion protein
proinsulin
canine
sequence
feline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247029510A
Other languages
English (en)
Korean (ko)
Inventor
사만다 제이. 버스필드
매튜 제이. 윌슨
Original Assignee
스카우트 바이오, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스카우트 바이오, 인코포레이티드 filed Critical 스카우트 바이오, 인코포레이티드
Publication of KR20240167718A publication Critical patent/KR20240167718A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020247029510A 2022-03-01 2023-03-01 인슐린 융합 단백질 Pending KR20240167718A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263315296P 2022-03-01 2022-03-01
US63/315,296 2022-03-01
PCT/US2023/063510 WO2023168288A2 (en) 2022-03-01 2023-03-01 Insulin fusion protein

Publications (1)

Publication Number Publication Date
KR20240167718A true KR20240167718A (ko) 2024-11-27

Family

ID=87884362

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247029510A Pending KR20240167718A (ko) 2022-03-01 2023-03-01 인슐린 융합 단백질

Country Status (11)

Country Link
US (1) US20250188144A1 (https=)
EP (1) EP4486796A4 (https=)
JP (1) JP2025507929A (https=)
KR (1) KR20240167718A (https=)
CN (1) CN119562965A (https=)
AU (1) AU2023228668A1 (https=)
CA (1) CA3245376A1 (https=)
CL (1) CL2024002605A1 (https=)
IL (1) IL315354A (https=)
MX (1) MX2024010693A (https=)
WO (1) WO2023168288A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120173090B (zh) * 2025-05-21 2025-07-29 华中农业大学 猫血清白蛋白突变体、及其cho细胞表达方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002364586A1 (en) * 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US9505823B2 (en) * 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
CA2676932C (en) * 2007-02-01 2015-11-24 Technion Research & Development Foundation Ltd. Albumin fibers and fabrics and methods of generating and using same
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
BR112014015156A2 (pt) * 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
WO2022098906A1 (en) * 2020-11-04 2022-05-12 The Trustees Of The University Of Pennsylvania Viral vectors encoding canine insulin for treatment of metabolic diseases in dogs
AU2023228669A1 (en) * 2022-03-01 2024-09-19 Scout Bio, Inc. Viral vector genome encoding an insulin fusion protein

Also Published As

Publication number Publication date
JP2025507929A (ja) 2025-03-21
CA3245376A1 (en) 2023-09-07
US20250188144A1 (en) 2025-06-12
WO2023168288A2 (en) 2023-09-07
AU2023228668A1 (en) 2024-09-19
WO2023168288A3 (en) 2023-09-28
MX2024010693A (es) 2024-12-06
EP4486796A4 (en) 2026-03-04
IL315354A (en) 2024-11-01
CN119562965A (zh) 2025-03-04
EP4486796A2 (en) 2025-01-08
CL2024002605A1 (es) 2025-07-11

Similar Documents

Publication Publication Date Title
JP6978407B2 (ja) Ｇｌｐ−１及び代謝性疾患を治療するための組成物におけるその使用
US20230405150A1 (en) Viral vector encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases in felines
JP7840319B2 (ja) Ｇｌｐ－１受容体アゴニスト融合物をコードするウイルスベクター及び代謝性疾患の治療におけるその使用
US20250388926A1 (en) Viral vector genome encoding an insulin fusion protein
US10736970B2 (en) Polypeptide complex of titin-telethonin beta-pleated sheet structure as polypeptide drug carrier, method of using the polypeptide complex, and fusion protein complex thereof
US20250188144A1 (en) Insulin fusion protein
JP2024509792A (ja) ファブリー病の治療のための組成物及び方法
US20250171515A1 (en) Aav vectors for delivery of glp-1 receptor agonist fusions
US20250186613A1 (en) Viral vectors encoding glp-2 receptor agonist fusions and uses thereof in treating short bowel syndrome
CN116376921A (zh) 一种用于治疗糖尿病的aav载体及其用途
HK40098913A (zh) 工程化α-GAL A肽及其功能变体和治疗法布里病的相关方法
HK40098913B (zh) 工程化α-GAL A肽及其功能变体和治疗法布里病的相关方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000